Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

07 3737 4500

PO Box 3787

South Brisbane QLD 4101

Dr Naadir Gutta

MBBCh (SA), FRACP, FRCPA

  • Clinical Haematologist

Biography

Dr Naadir Gutta is committed to providing his patients with personalised treatment plans, tailored to suit their individual needs. He brings a compassionate, measured approach to his practice to ensure his patients are supported throughout their treatment and beyond.

Dr Naadir Gutta is an experienced clinical haematologist at Icon Cancer Centre Greenslopes and Icon Cancer Centre South Brisbane. He completed his undergraduate medical training in South Africa and then completed his specialist haematology training in Queensland. In addition to his private work, Dr Gutta is Clinical Director of Haematology at Mater Hospital. He is also a fellow of the Royal Australasian College of Physicians (FRACP) and Royal College of Pathologists of Australasia (FRCPA).

Dr Gutta maintains a strong interest in clinical research and education, actively completing research in the treatment of malignant and non-malignant haematological conditions. He is involved in general practitioner and undergraduate medical education, providing educational support and delivering formal lectures at the University of Queensland.

His clinical experience covers a broad range of malignant and non-malignant blood disorders including myeloma, lymphoma, chronic lymphocytic leukaemia, thrombosis and haemostasis. Dr Gutta also has a keen interest in obstetric haematology.

Publications

  • Transfusion-related Acute Lung Injury (TRALI): a review of current literature and presentation of reported TRALI cases in Queensland between 1999 – January 2013. Gutta, G. Hodges, M. Kelly, L. Phillips, S.J. Bryant, K. Goodison, G. Mraz, R. Holdsworth & S. Baidya. HAA 2013 Annual Scientific Meeting, 2013.

  • Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin’s lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure. M. Fong, S. Boyle & N. Gutta. BMJ Case Reports CP, 2019; 12.

  • Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. Bhurani, L. Admojo, C. Van Der Weyden, R. Twigger, A. Bazargan, H. Quach, A. Zimet, L. Coyle, J. Lindsay, D. Radeski, E. Hawkes, G. Kennedy, I. Irving, N. Gutta, J.Trotman, J. Yeung, L. Dunlop, M. Hua, P. Giri, S. Yuen, S. Panicker, S. Moreton, L. Khoo, A. Scott, D. Kipp, A. McQuillan, C. McCormack, M. Dickinson & H. Prince. Leukemia & Lymphoma, 2020.